Oral Surgery Valuation Multiple 2026: Private Buyer vs. DSO

Key Takeaways for Oral Surgery Owners

• Normalized EBITDA is the key number buyers focus on for 2026 valuations. It replaces owner compensation with market-rate associate costs and adjusts for one-time or personal expenses.
• Private-buyer (doctor-to-doctor) sales often close at 6.5x–9.0x Seller’s Discretionary Earnings (SDE) with shorter work-back periods. DSO and private equity buyers typically pay 7.0x–12.0x adjusted EBITDA and usually require longer employment agreements plus 15–30% rollover equity.
• Owner-production concentration above 60–70% of collections can compress multiples by 1–2 turns. Adding an associate and diversifying referrals can materially increase valuation.
• Referral-network strength, in-house anesthesia, CBCT imaging, and full-arch implant capability are consistent infrastructure premiums that separate top-of-range OMS valuations from mid-range ones.
• McLerran & Associates has completed roughly 2,000 practice sales and often delivers an average 30% valuation lift. Request a side-by-side valuation review to see how your oral surgery practice might price in today’s market.

Normalizing EBITDA Before an Oral Surgery Sale

Normalized EBITDA is not the number on your tax return. It is a restated profit figure that reflects what a sophisticated buyer such as a DSO, a private equity platform, or a well-advised individual dentist will actually underwrite when pricing your practice. Getting this number right before going to market can be the most important step in shaping the story around your practice’s value.

Based on McLerran & Associates’ experience evaluating more than 10,000 dental practices, the most common normalization adjustments for an oral surgery practice fall into several recurring categories, with owner compensation usually representing the largest single add-back:

• Owner compensation to market-rate associate. The owner’s total compensation package, including salary, distributions, benefits, and personal expenses run through the practice, is replaced with the cost of hiring a market-rate oral surgeon to perform equivalent clinical production. Market-rate replacement compensation for oral surgeons is typically higher than the 30% benchmark often used for general dentistry. This adjustment is frequently the largest EBITDA add-back and the item most often challenged during a Quality of Earnings review, which is a buyer’s detailed financial audit.
• Related-party rent adjustment. When the owner also owns the building, rent on the practice profit-and-loss statement is adjusted to estimated market rent, typically 5–7% of collections. Below-market rent produces a negative adjustment because the buyer will pay higher rent after closing.
• Discretionary personal add-backs. Common discretionary add-backs include personal vehicle expenses, compensation to family members without a true business role, personal cell phone and internet, personal travel booked as continuing education, and excessive entertainment or meals.
• One-time and non-recurring items. One-time costs such as lawsuit settlements, non-recurring legal fees, limited-duration consulting engagements, pre-sale preparation costs, and unusual equipment repairs are added back because they do not reflect the practice’s ongoing earnings power.
• Revenue normalization. Buyers normalize revenue to a net collections methodology so they can compare practices consistently when some report production-based usual, customary, and reasonable (UCR) revenue and others report net collected revenue.
• Associate ramp-up add-backs. DSO buyers normalize associate-doctor production guarantees to actual production-based compensation at market collection rates. They add back to EBITDA when base-salary guarantees exceed realized production during associate ramp-up periods.

These adjustments only create value if they survive buyer scrutiny. A weak normalization analysis that misses add-backs or cannot be supported with documentation often gets renegotiated downward during the buyer’s Quality of Earnings review. McLerran’s CPA-led EBITDA analysis is designed to hold up under that scrutiny so the agreed value is more likely to remain intact between letter of intent and closing.

Request a diligence-grade normalization analysis to see how McLerran & Associates’ CPA-led EBITDA review can affect your oral surgery practice’s valuation.

Owner-Production Concentration and Its Impact on Value

Owner-production concentration can be one of the most consequential and most frequently underestimated variables in an oral surgery valuation. Buyers are not simply buying historical earnings. They are buying earnings they believe will transfer and remain stable after the sale. When a large share of production depends on a single surgeon who plans to exit, buyers price that risk directly.

Owner-production concentration affects valuation through a predictable progression. It begins with explicit multiple compression at certain thresholds, continues through changes in deal structure, and ends with a measurable premium for practices that have associate depth. The key inflection points include the following:

• The 70% threshold. Practices where the owner produces 60 to 70 percent or more of collections carry higher post-close transition risk that buyers often reflect in the multiple.
• The 90% discount zone. Practices where the owner performs a very high percentage of production can face a valuation reduction because buyers cannot confidently underwrite revenue that may leave with the seller.
• The multiple compression example. High owner dependence carries the multiple compression described earlier, often amounting to 1–2 full turns of EBITDA.
• Structural responses from buyers. High owner dependence prompts DSO buyers to protect themselves through a mix of pricing and structural changes. They may lower the multiple to reflect transition risk, reduce cash at close to limit exposure, require longer seller employment commitments to support continuity, increase rollover equity to align incentives, or add earnout and employment-linked terms that tie final proceeds to realized results.
• The associate-depth premium. Practices with associate depth, such as two or more producing associates, and structured associate compensation tied to production tend to trade at a premium relative to solo-surgeon practices because buyers view their earnings as more transferable.
• Adding one associate can move the multiple. Adding one producing associate can move an owner-dependent practice up by about a full turn of EBITDA because buyers often pay more for collections that transfer cleanly after the sale.

McLerran’s concentration-risk analysis quantifies where your practice sits on this spectrum and models the valuation impact before the practice goes to market. That gives owners the option to reduce risk strategically rather than discover the discount during negotiations.

Request a concentration-risk analysis to understand how your owner-production percentage may affect your 2026 oral surgery valuation multiple.

Referral Networks, Anesthesia, and Other OMS Premium Drivers

Oral surgery practices are referral-dependent businesses. The durability of those referral relationships, combined with the surgical infrastructure that supports them, can be some of the main factors that separate a top-of-range valuation from a mid-range one. Buyers often test referral portability directly before they support premium multiples.

• Diversified GP referral relationships. Buyers of specialty dental practices test whether referrals are likely to follow the practice rather than the departing surgeon and whether production is concentrated in one clinician. Non-portable referrals reduce post-close volume predictability. A broad, documented referral base across multiple general dentist relationships can be a meaningful value driver.
• In-house anesthesia capability. Oral surgery practices often achieve the highest valuation multiples among dental specialties when they feature in-house anesthesia capabilities, hospital privileges, and multi-surgeon capacity.
• CBCT and advanced imaging. Cone beam CT (CBCT), a three-dimensional imaging system used for surgical planning, is a recognized infrastructure asset. It supports premium positioning with buyers that are building surgical networks.
• Full-arch implant capability. Full-arch implant capability and in-house 3D printing with same-day surgical guides were distinct pricing levers that supported the top of the OMS multi-site band from 2024 through Q2 2026.
• Specialty overlay premium. Specialty overlay inside a general practice group, including in-house oral surgery, can add a premium to blended multi-site multiples.
• Post-close transition commitment. A seller who stays after closing to introduce patients and support referrals can reduce retention risk for the buyer and help support the valuation multiple. Structured post-close doctor-transition arrangements, such as a retiring doctor remaining as an associate for 6–12 months, formal patient introduction protocols, and staff retention bonuses, can be material to the achievable multiple.

These premium drivers do not create value automatically. They need to be documented, highlighted clearly in marketing materials, and supported during diligence. McLerran’s process focuses on surfacing and protecting every premium your oral surgery practice has earned.

Discuss your infrastructure and referral-network premiums to see which specific factors may support a higher valuation for your practice.

Comparing Outcomes: Private Buyer vs. DSO in 2026

The headline multiple is only the starting point. What an oral surgery owner actually keeps depends on deal structure, tax treatment, post-close work-back commitments, and the quality of the buyer. McLerran’s side-by-side modeling, based on approximately 2,000 closed transactions, translates multiples into practical after-tax economics across both private-buyer and DSO paths.

• Net proceeds comparison. A private-buyer (doctor-to-doctor) transaction typically closes with a higher cash-at-close percentage and a shorter work-back of roughly 4–8 weeks, although the headline multiple may be lower than a DSO offer on the same normalized EBITDA. That multiple difference often exists because DSO deals shift more risk to the seller. Rollover equity is usually required at 15–30% of total consideration, and deals often close at 60–75% cash at close, which means a meaningful share of proceeds is deferred and at risk. The higher DSO multiple can be viewed as compensation for that deferred, at-risk component.
• Equity structure risk. DSO equity can be held at the joint-venture level, which usually pays distributions and may offer a lower ceiling, or at the holding-company level, which may not pay distributions but can have a higher upside. Up to roughly 40% of a DSO deal can be paid in equity rather than cash, so the quality and financial health of the DSO itself become critical factors.
• Post-close work-back commitments. Provider risk and clinical continuity have become leading reasons DSOs walk away from deals. Buyers now more consistently require a minimum 5-year post-close employment term. Private-buyer walk-away sales usually require only a 4–8-week work-back.
• Tax treatment differences. A significant portion of a DSO deal’s proceeds may be taxed at long-term capital gains rates instead of ordinary income rates. That difference can create a meaningful after-tax advantage that a simple gross multiple comparison does not show.
• Market conditions in 2026. Headline EBITDA multiples have remained relatively steady for 2 consecutive years. The spread between the best and middle-tier offers on the same practice has widened, so competitive tension, not just overall market conditions, can be a primary driver of outcomes. About 78% of surveyed DSOs anticipate recapitalization within 12–36 months, which can create leverage for sellers negotiating with buyers preparing for those events.
• The cost of a single-buyer negotiation. Deal structures have shifted toward less cash at closing and more contingencies such as promissory or maintenance notes, 5-year employment agreements, and EBITDA maintenance requirements. A competitive, multi-buyer process is often designed to push back against those terms.

McLerran’s structured, auction-style DSO bid process typically generates around 10 offers within 45–60 days, which creates the competitive tension that can improve both price and terms. Owners who sell without that competition negotiate against a counterparty that prices deals every week, and the difference in outcome can be measurable.

Request a side-by-side, after-tax outcome model to compare private-buyer and DSO paths for your oral surgery practice.

Frequently Asked Questions

What is a realistic 2026 EBITDA multiple range for an oral surgery practice?

The range can be wide and practice-specific. Single-office, solo-surgeon oral surgery practices often transact at multiples tied to Seller’s Discretionary Earnings, which is a measure of total owner benefit. Multi-site groups with meaningful associate depth and more than $2 million in normalized EBITDA have tended to command higher multiples on an adjusted EBITDA basis. Oral surgery has consistently carried one of the highest specialty premiums in dentistry, often above equivalent-sized general practices. Factors that can move a practice toward the top of its range include associate depth, diversified referral relationships, in-house anesthesia, full-arch implant capability, and a commercial-weighted payer mix. McLerran’s valuation process quantifies where your practice lands and why before you go to market.

How does owner-production concentration affect my oral surgery valuation?

Owner-production concentration can be one of the most significant discounting factors in the analysis. When the selling surgeon produces most of the practice’s revenue, buyers need to estimate how much of that revenue will survive the transition. As concentration rises, buyers often respond by lowering the multiple, reducing cash at close, or shifting value into earnouts and employment-linked contingencies. As noted earlier, practices above the 60–70% owner-production threshold are subject to explicit concentration-risk pricing. Practices with 2 or more producing associates and structured, production-based associate compensation are viewed as lower-risk assets and are priced accordingly. The positive news is that concentration risk can often be addressed before a sale, and McLerran’s evaluation process is designed to identify those opportunities early.

What normalization adjustments matter most when preparing an oral surgery practice for sale?

The largest adjustment, as detailed earlier, is owner compensation normalization, which replaces actual owner pay with market-rate replacement cost for an oral surgeon performing similar production. For oral surgery, market-rate replacement compensation is usually a higher percentage of production than for general dentistry because of procedural complexity. Other material adjustments often include related-party rent, which is adjusted to market when the owner also owns the building, documented discretionary personal expenses run through the practice, and one-time or non-recurring costs that do not reflect ongoing earnings power. Each adjustment needs to be documented and defensible because a buyer’s Quality of Earnings team will review them closely. McLerran’s CPA-led normalization process is built to support add-backs that can withstand that level of review so the agreed value is less likely to erode between letter of intent and closing.

How do referral networks and surgical infrastructure affect what a buyer will pay?

As discussed in the referral and infrastructure section above, referral relationships and surgical infrastructure can be some of the main premium drivers that separate a top-of-range oral surgery valuation from a mid-range one. Buyers test whether referrals are portable, meaning they will follow the practice rather than the departing surgeon, before they support premium multiples. A broad, documented referral base across multiple general dentist relationships can be a meaningful value driver. In-house anesthesia capability, CBCT imaging, hospital privileges, and full-arch implant capability with in-house 3D printing have all functioned as distinct pricing levers at the top of the multi-site OMS band. A seller who commits to a structured post-close transition, including formal patient introduction protocols and a meaningful clinical presence for 6–12 months, can also add to the achievable multiple by reducing the buyer’s perception of transition risk.

Why does McLerran & Associates run both private-buyer and DSO transactions for oral surgery practices?

The appropriate path for any oral surgery owner depends on the specific practice, the owner’s financial goals, and personal priorities. Owners cannot know which path serves them better without modeling both. A private-buyer transaction may deliver a higher cash-at-close percentage and a shorter work-back commitment. A DSO transaction may deliver a higher enterprise value, but with a meaningful equity component, a longer employment commitment, and post-close economics that depend heavily on the quality of the buyer. McLerran works both paths in roughly equal measure, with approximately a 50/50 split, so the firm has no incentive to steer an owner toward one option. Each engagement begins with a side-by-side valuation that quantifies the practice’s worth in both markets so the owner can choose based on data rather than guesswork.